Browsing by Author "Soyyiğit Ş."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Physical activity and dietary habits in patients with asthma: How is it related to asthma control?
    (Elsevier Ltd, 2023) Aydın Ö.; Çelebi Sözener Z.; Mungan D.; Özbey Ü.; Balaban S.; Gökmen D.; Zergeroğlu A.M.; Gemicioğlu B.; Yorgancıoğlu A.; Havlucu Y.; Yıldız F.; Argun Barış S.; Çerçi P.; Dursun A.B.; Kalpaklıoğlu F.; Baççıoğlu A.; Atış Naycı S.; Sercan Özgür E.; Kendirlinan R.; Koca Kalkan İ.; Köycü Buhari G.; Yılmaz İ.; Türk M.; Göksel Ö.; Erdinç M.; Damadoğlu E.; Kalyoncu A.F.; Karakaya G.; Ediger D.; Oğuzülgen I.K.; Türktaş H.; Soyyiğit Ş.; Paşaoğlu Karakış G.; Sekibağ Y.; Kızılırmak D.; Dönmez H.; Boğatekin G.; Çakmak M.E.; Kaya S.B.; Günaydın F.E.; Çelik G.
    Aims: In this study, we aimed to determine the PA and dietary habits of patients with asthma and whether asthma control had a role in these habits. Methods: Adult patients with asthma were included. Three questionnaires were administered to the patients. and daily step counts were recorded for one week. Asthma control level and severe asthma attacks in the previous year were assessed. Results: A total of 277 patients were included. One hundred eighty-two (65.3%) of the patients were overweight/obese. According to FFQ, none of the food groups were comsumed in recommended levels. According to the IPAQ scores, 82.7% of the patients had mild physical activity. The daily step counts and the PA domain of the HLBS-II in obese patients were lower than the nonobese patients (p = 0.001 and p = 0.034,respectively). The rate of obese patients (n = 9; 50%) was higher in the uncontrolled patients. Conclusion: In our study, the majority of patients were physically inactive. Few patients consumed the recommended amount of foods. Being overweight seems to be a significant barrier to the healthy life behaviors. Although these behaviours do not seem to have an effect on asthma controlling this study, further prospective placebo-controlled studies are needed. © 2022 Elsevier Ltd
  • No Thumbnail Available
    Item
    Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry
    (Exon Publications, 2025) Beyaz Ş.; Erdinç M.; Hayme S.; Aslan A.F.; Aydın Ö.; Gökmen D.; Buhari G.K.; Sözener Z.Ç.; Gemicioğlu B.; Bulut İ.; Örçen C.; Özdemir S.K.; Keren M.; Damadoğlu E.; Yakut T.; Kalpaklıoğlu A.F.; Baccıoğlu A.; Yalım S.A.; Yılmaz İ.; Kalkan İ.K.; Uysal M.A.; Niksarlıoğlu E.Y.Ö.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayc S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Göksel Ö.; Karaoğlanoğlu S.; Erkekol F.Ö.; Isık S.R.; Yıldız F.; Yavuz Y.; Karadoğan D.; Bozkurt N.; Şeker Ü.; Oğuzülgen İ.K.; Başyiğit İ.; Barış S.A.; Uçar E.Y.; Erdoğan T.; Polatlı M.; Ediger D.; Günaydın F.E.; Türk M.; Pür L.; Katran Z.Y.; Sekibağ Y.; Aykaç E.F.; Mungan D.; Gül Ö.; Cengiz A.; Akkurt B.; Özden Ş.; Demir S.; Ünal D.; Can A.; Gümüşburun R.; Boğatekin G.; Akten H.S.; İnan S.; Öğüş A.C.; Kavas M.; Yuluğ D.P.; Çakmak M.E.; Kaya S.B.; Alpagat G.; Özgür E.S.; Uzun O.; Gülen Ş.T.; Pekbak G.; Kızılırmak D.; Havlucu Y.; Dönmez H.; Arslan B.; Çetin G.P.; Soyyiğit Ş.; Kara B.Y.; Karakış G.P.; Dursun A.B.; Kendirlinan R.; Öztürk A.B.; Sevinç C.; Şimşek G.Ö.; Abadoğlu Ö.; Çerçi P.; Yücel T.; Yorulmaz İ.; Tezcaner Z.Ç.; Tatar E.Ç.; Süslü A.E.; Özer S.; Dursun E.; Yorgancıoğlu A.; Çelik G.E.
    Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.76% (n = 1268; mean age: 46.2 ± 14.3 years), predominantly females (~76%), received montelukast. Montelukast users showed higher rates of allergic rhinitis (P < 0.001), hyper-sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) (P = 0.008), and chronic rhinosi-nusitis (P = 0.008). Montelukast group also had higher atopy and total IgE levels and tended to be more eosinophilic. Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P < 0.001). Patients receiving Steps 4 and 5 treatments are more likely to be prescribed montelukast (P < 0.001). Montelukast usage was higher among patients with uncontrolled asthma [ACT< 20 (OR:1.29, 95%CI:1.052–1.582, P = 0.014)]. In addition, logistic regression analyses identified the main factors associated with increased montelukast use as; female gender (OR:1.33, 95%CI:1.041–1.713, P = 0.02), presence of atopy (OR:1.46, 95%CI:1.157–1.864, P = 0.002), comorbid allergic rhinitis (OR:2.12, 95%CI:1.679–2.293, P < 0.001), and severe asthma (OR:2.18, 95%CI:1.712–2.784, P < 0.001). These findings reveal that montelukast use is prevalent among asthma patients, particularly in females, middle-aged adults, and those with comorbid allergic rhinitis, uncontrolled asthma, or specific asthma phenotypes, underscoring the factors that influence its prescription in asthma management. © 2025 Codon Publications.